Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States

Abstract

Objective

Most patients with nasopharyngeal carcinoma (NPC) in the United States are diagnosed with stage III-IV disease. Screening for NPC in endemic areas results in earlier detection and improved outcomes. We examined the cost-effectiveness of screening for NPC with plasma Epstein-Barr virus DNA among Asian American men in the United States.

Study Design

We used a Markov cohort model to estimate discounted life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios for screening as compared with usual care without screening.

Setting

The base case analysis considered onetime screening for 50-year-old Asian American men.

Subjects and Methods

Confirmatory testing was magnetic resonance imaging and nasopharyngoscopy. Cancer-specific outcomes, health utility values, and costs were determined from cancer registries and the published literature.

Results

For Asian American men, usual care without screening resulted in the detection of NPC at stages I, II, III-IVB, and IVC among 6%, 29%, 54%, and 11% of those with cancer, respectively, whereas screening resulted in earlier detection with a stage distribution of 43%, 24%, 32%, and 1%. This corresponded to an additional 0.00055 QALYs gained at a cost of $63 per person: an incremental cost of $113,341 per QALY gained. In probabilistic sensitivity analysis, screening Asian American men was cost-effective at $100,000 per QALY gained in 35% of samples.

Conclusion

Although screening for NPC with plasma Epstein-Barr virus DNA for 50-year-old Asian American men may result in earlier detection, in this study it was unlikely to be cost-effective. Screening may be reasonable for certain subpopulations at higher risk for NPC, but clinical studies are necessary before implementation.

Keywords

nasopharyngeal carcinoma Epstein-Barr virus screening cost-effectiveness

Get full access to this article

View all access options for this article.

References

Forman

Bray

Brewster

et al . Cancer Incidence in Five Continents. Vol 10. Lyon, France: International Agency for Research on Cancer; 2014. IARC scientic publication 164.

Chan

KCA

Woo

JKS

King

et al . Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377:513-522.

Surveillance Research Program. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database, SEER 9 Regs Research Data, Nov 2016 Sub (1973-2014). Bethesda, MD: National Cancer Institute; 2017.

Blanchard

Lee

Marguet

et al . Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645-655.

Xiao

W-W

Han

T-X

Chen

C-Y

Huang

Zhao

Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:1070-1076.

S-F

Han

Zhao

et al . Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82:327-333.

Wei

Sham

JST

. Nasopharyngeal carcinoma. Lancet Lond Engl. 2005;365:2041-2054.

Zeng

Zhong

et al . Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology. 1983;20:190-194.

Zeng

Zhang

et al . Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985;36:545-547.

10.

Chan

et al . Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59:1188-1191.

11.

Brennan

Chick

Davies

A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295-1310.

12.

Langner

Buelow

Fleck

Angermaier

Kirsch

Management of intracranial incidental findings on brain MRI. ROFO Fortschr Geb Rontgenstr Nuklearmed. 2016;188:1123-1133.

13.

Håberg

Hammer

Kvistad

et al . Incidental intracranial findings and their clinical impact: the HUNT MRI study in a general population of 1006 participants between 50-66 years. PloS One. 2016;11:e0151080.

14.

Laury

Oyesiku

Hadjipanayis

Delgaudio

Wise

SK.

Incidental sinonasal findings identified during preoperative evaluation for endoscopic transsphenoidal approaches. Am J Rhinol Allergy. 2013;27:202-205.

15.

Lang

BH-H

Chu

KK-W

Tsang

RK-Y

Wong

BY-H

. Evaluating the incidence, clinical significance and predictors for vocal cord palsy and incidental laryngopharyngeal conditions before elective thyroidectomy: is there a case for routine laryngoscopic examination? World J Surg. 2014;38:385-391.

16.

Gold

Siegel

Russell

Weinstein

MC.

Cost-effectiveness in Health and Medicine. Oxford, England: Oxford University Press; 1996.

17.

Ubel

Hirth

Chernew

Fendrick

AM.

What is the price of life and why doesn’t it increase at the rate of inflation?

Arch Intern Med. 2003;163:1637-1641.

18.

Bray

Colombet

Mery

et al . Cancer incidence in five continents. Vol 11. http://ci5.iarc.fr. Accessed December 16, 2018.

19.

Ghalanos

Theussl

Rsolnp: General Non-linear Optimization Using Augmented Lagrange Multiplier Method. https://cran.r-project.org/web/packages/Rsolnp/Rsolnp.pdf. Published December 28, 2015. Accessed October 5, 2017.

20.

Interior Algorithms for Linear, Quadratic, and Linearly Constrained Non-linear Programming [dissertation]. Stanford, CA: Stanford University; 1988.

21.

Shonkwiler

Spruill

MC.

Random Restarts in Global Optimization. Atlanta, GA: Georgia Institute of Technology; 1994.

22.

Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple cause of death file, 2004-2014. http://wonder.cdc.gov/mcd-icd10.html. Accessed April 18, 2018.

23.

Centers for Medicare. Clinical laboratory fee schedule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files-Items/17CLAB.html. Published December 23, 2016. Accessed December 2, 2017.

24.

Centers for Medicare & Medicaid Services. Physician fee schedule search. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed December 1, 2017.

25.

Centers for Medicare & Medicaid Services. Health expenditures by age and gender. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Age-and-Gender.html. Published November 21, 2017. Accessed December 2, 2017.

26.

Gourin

Fakhry

Quon

et al . Treatment, survival, and costs of oropharyngeal cancer care in the elderly. Laryngoscope. 2018;128:1103-1112.

27.

Al-Sarraf

LeBlanc

Giri

et al . Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.

28.

Lee

AWM

Tung

et al . A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017;123:4147-4157.

29.

Tuan

JKL

Ong

et al . Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. Radiother Oncol. 2012;104:305-311.

30.

Jacobson

Epstein

Eichmiller

et al . The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012;4:15.

31.

Bekelis

Gottlieb

et al . Medicare expenditures for elderly patients undergoing surgical clipping or endovascular intervention for unruptured cerebral aneurysms. J Neurointerventional Surg. 2017;9:324-328.

32.

US Bureau of Labor Statistics. CPI inflation calculator. https://www.bls.gov/data/inflation_calculator.htm. Accessed December 2, 2017.

33.

Gareen

Duan

Greco

et al . Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer. 2014;120:3401-3409.

34.

Tosteson

ANA

Fryback

Hammond

et al . Consequences of false-positive screening mammograms. JAMA Intern Med. 2014;174:954-961.

35.

Loimu

Mäkitie

Bäck

et al . Health-related quality of life of head and neck cancer patients with successful oncological treatment. Eur Arch Otorhinolaryngol. 2015;272:2415-2423.

36.

Pow

EHN

Kwong

DLW

McMillan

et al . Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol. 2006;66:981-991.

37.

Nichol

Sengupta

Globe

DR.

Evaluating quality-adjusted life years: estimation of the Health Utility Index (HUI2) from the SF-36. Med Decis Making. 2001;21:105-112.

38.

Truong

Zhang

Rosenthal

et al . Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced head and neck carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2017;97:687-699.

39.

Del Barco Morillo

Mesía

Adansa Klain

et al . Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer: TTCC-2009-03/VECTITAX study. Oral Oncol. 2016;62:54-59.

40.

Goldhaber-Fiebert

Jalal

HJ.

Some health states are better than others: using health state rank order to improve probabilistic analyses. Med Decis Making. 2016;36:927-940.

41.

Friborg

Wohlfahrt

Koch

Storm

Olsen

Melbye

Cancer susceptibility in nasopharyngeal carcinoma families—a population-based cohort study. Cancer Res. 2005;65:8567-8572.

42.

Liu

Chang

Liu

et al . Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. Cancer. 2017;123:2716-2725.

43.

Loh

Goh

Hsieh

W-S

Tan

Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg. 2006;132:82-85.

44.

Liu

Fang

Chang

Cancer risk in the relatives of patients with nasopharyngeal carcinoma—a register-based cohort study in Sweden. Br J Cancer. 2015;112:1827-1831.

45.

US Census Bureau, Population Division. Annual estimates of the resident population by sex, single year of age, race alone or in combination, and Hispanic origin for the United States: April 1, 2010 to July 1, 2017. http://factfinder.census.gov. Accessed December 19, 2018.

46.

Hildesheim

Invited commentary: Epstein-Barr virus–based screening for the early detection of nasopharyngeal carcinoma: a new frontier. Am J Epidemiol. 2013;177:251-253.

47.

Zong

Sham

et al . Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer. 1992;69:3-7.

48.

Liu

M-F

Huang

Q-H

et al . Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in southern China. Am J Epidemiol. 2013;177:242-250.

49.

K-W

Chung

GT-Y

K-F.

Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22:79-86.

50.

Q-T

Zhang

Cao

et al . An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19:2208-2215.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.52 MB